New guidance released by FDA provides advice for sponsors on developing drugs for treating Clostridioides difficile infection (CDI). The draft guidance discusses how to design trials and trial populations, efficacy and safety endpoints, nonclinical studies, and pharmacokinetic studies.

New recommendations put forth from ACIP last week addressed the use of the 20-valent conjugate pneumococcal vaccine (PCV20, also called Prevnar 20) in adults with a vaccine history that includes the 13-valent conjugate vaccine (PCV13, also known as Prevnar 13).

Researchers wanted to find out if ivermectin compared to placebo shortened symptom duration for adult patients in the United States with symptomatic mild to moderate COVID-19. According to results of the randomized clinical trial published in JAMA on October 21, 2022, the research team found that among outpatients with mild to moderate COVID-19, treatment with ivermectin compared with placebo did not significantly improve time to recovery

New CDC findings highlight the hidden dangers of antihistamines for users who have concomitant exposure to opioids.

Clinicians treating patients with COVID-19  who are at risk for progression to acute disease should be aware of potential drug–drug interactions when the oral antiviral treatment nirmatrelvir/ritonavir (Paxlovid—Pfizer) is administered to people taking common cardiovascular drugs, experts warn in a new Journal of the American College of Cardiology article.